Several FXI inhibitors have entered Phase 3 trials: abelacimab and milvexian for stroke prevention in AF, and FXI-ASO for AF (ongoing AF trials); milvexian and osocimab for VTE prophylaxis; AB023 for stroke prevention in hemodialysis, etc. No pivotal results are published yet (as of 2025) for most of these. This evidence concerns the gene F11 and stroke disorder.